A phase II study of the somatostatin analog sandostatin LAR in patients with androgen independent prostate cancer

Trial Profile

A phase II study of the somatostatin analog sandostatin LAR in patients with androgen independent prostate cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Octreotide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Mar 2010 Primary endpoint 'Prostate specific antigen' has not been met.
    • 05 Mar 2010 Results presented at ASCO Genitourinary Cancers Symposium 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top